<DOC>
	<DOC>NCT00582894</DOC>
	<brief_summary>To evaluate engraftment and toxicity of a reduced intensity preparative regimen for patients who receive a matched related or unrelated donor allogeneic stem cell transplant (ASCT) for malignant hematological diseases</brief_summary>
	<brief_title>Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematological Diseases</brief_title>
	<detailed_description>Primary Endpoints: 1. Engraftment of donor cells 2. Regimen related toxicities Secondary Endpoints: 1. Disease-free survival 2. Overall survival</detailed_description>
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Performance status 02 Ejection fraction &gt; 30% AST/ALT and bilirubin not &gt; 4 times normal Creatinine clearance greater than 70 ml/min. FEV1 greater than 1.0 and diffusion capacity greater than 40% Age 1875 years Patients must be at high risk for conventional regimen related toxicity Malignant hematologic disease that would otherwise be considered treatable with ASCT Does not meet the above Inclusion criteria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Allogenic stem cell transplant</keyword>
	<keyword>Hematologic diseases</keyword>
</DOC>